grant
Program to block age-related pulmonary fibrosis and restore lung regeneration
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 15 Feb 2026Deadline 31 Dec 2032
NIHUS FederalResearch GrantFY2026AgeAgingAlveolarAttenuatedBasal CellBeliefCell BodyCell DifferentiationCell Differentiation processCell LineCellLineCellsCharacteristicsClinicCytology and PathologyCytopathologyDataDevelopmentDiseaseDisorderElderlyElementsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpigenetic ageEpithelial CellsEpitheliumFDA licensed drugsFDA-approved agentsFDA-approved drugFDA-approved medicationsFDA-approved pharmaceuticalsFDA-approved therapeutic agentFibrosing AlveolitisFibrosisFood and Drug Administration approved drugFood and Drug Administration approved medicationsFood and Drug Administration approved pharmaceuticalsGene TranscriptionGenesGenetic TranscriptionHIF 1 alphaHIF-1alphaHIF1-AlphaHIF1AHIF1A geneHIF1αHumanImpairmentInflammation MediatorsInjuryLinkLungLung Alveolar EpitheliaLung Respiratory SystemLung Tissue FibrosisLung tissue regenerationMOP1MedicalModern ManMorbidityOutcomePatientsPersonal SatisfactionPulmonary FibrosisRNA ExpressionRegulationResearchRespiratory BronchioleRiskSelf-Help GroupsStrains Cell LinesStressStructureStructure of respiratory bronchioleSupport GroupsTherapeuticTranscriptionType II PneumocyteWorkadvanced ageage associatedage correlatedage dependentage linkedage relatedage specificagedagesalveolar epitheliumalveolar type II cellattenuateattenuatescellular differentiationcultured cell linedevelopmentaldiffuse interstitial pulmonary fibrosisepigeneticallyfibrosis in the lungfibrotic lung diseasefibrotic pulmonary diseasegeriatriciPSiPSCiPSCsidiopathic pulmonary fibrosisimprovedinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinflammatory mediatorinjurieslung fibrosislung functionlung regenerationmRNA Expressionmortalitynew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyprogramspromoterpromotorpulmonary functionpulmonary regenerationself help organizationsenior citizensmall moleculespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicstransdifferentiationwell-beingwellbeing
Description preview
ABSTRACT
In the US alone ~200,000 patients present yearly with Idiopathic Pulmonary Fibrosis (IPF), a relentlessly
progressive disorder with average survival of 3-5 years that is strongly linked to aging. No FDA approved drug
improves lung function or well-being, underscoring the medical need for new therapeutics. The central
premise of this…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click